Fresenius Kabi Launches Epinephrine Injection, Expands US Pharma Portfolio
Fresenius Kabi has launched Epinephrine Injection, USP, the first generic version of epinephrine in a 1mg/1mL vial, in the...
Trodelvy Gets Breakthrough Therapy for Lung Cancer
The FDA has granted Breakthrough Therapy Designation to Gilead Sciences’ Trodelvy for treating extensive-stage small cell lung cancerlung cancer...
Navigating IP in Clinical Trials: Insights from Joana Piriquito Santos
In the high-stakes world of pharmaceuticals, intellectual property (IP) rights are crucial for protecting innovation and ensuring returns on...
Strategic Navigation for Clinical Trials in Mid-Size Biopharma: Insights from Almirall
At SCOPE Summit Europe, Estrella García, PhD, an Executive Director at Almirall, shared her insights on navigating the complexities...
Naropa University and Center for Psychedelic Studies Separate
Naropa University’s Center for Psychedelic Studies has become an independent entity, the Memoru Center for Visionary Healing Arts, in...
Lerodalcibep Biologic License Application Submitted to FDA
LIB Therapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for Lerodalcibep, a novel PCSK9 inhibitor...
Contineum PIPE-791 Phase 1b PET Trial Begins Patient Dosing
Contineum Therapeutics has initiated a Phase 1b positron emission tomography (PET) trial for PIPE-791, a novel brain-penetrant, small molecule...
Navigating the Future of Endometriosis Diagnostics
In this interview, we spoke with Farideh Bischoff, PhD, Chief Medical Officer – Head of Diagnostics at HeranovaTM, about their innovative...
How Sangamo is Navigating the Future of Gene Therapy for Rare Diseases
In this interview, we speak with Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo Therapeutics, about the FDA’s accelerated approval...
Beigene’s Global MAT2A Inhibitor Licensing Deal
BeiGene, soon to be BeOne Medicines, has secured global licensing rights for SYH2039, a novel MAT2A inhibitor, from CSPC....